Effects of the Seminal Plasma Proteins Semenogelin (SEMG)/Seminal Vesicle Secretion 2 (SVS2) on Sperm Fertility pp.205-220. Yoshida, K, Iwamoto, T, & Yoshida, M In Human spermatozoa : maturation, capacitation and abnormalities, pages 205–220. Nova Biomedical Books, 2010., New York, 2010.
Effects of the Seminal Plasma Proteins Semenogelin (SEMG)/Seminal Vesicle Secretion 2 (SVS2) on Sperm Fertility pp.205-220 [link]Paper  abstract   bibtex   
After ejaculation, mammalian spermatozoa need to stay in the female reproductive tract for an appropriate time period before becoming fertilization competent. The molecular, biochemical, and physiological changes that occur to sperm while in the female tract are collectively referred to as capacitation. During this period, seminal plasma can both inhibit and stimulate sperm function and fertility mediated by the multifunctional actions of organic and inorganic components. The major functional proteins isolated and characterized in seminal plasma, which originate in the seminal vesicle, are the semenogelins (SEMGs) SEMG1 and SEMG2 in humans and the homologous protein seminal vesicle secretion 2 (SVS2) in mice. SEMGs are inhibitory factors that affect sperm motility and acrosome reaction. SVS2 also inhibits acrosome reaction and in vitro fertilization (IVF), and this action is considered to be a ―decapacitation factor‖. These proteins can bind to the sperm surface and simultaneously work to precapacitate the spermatozoa, thus shortening their fertilization lifespan. This binding is reversible, but this may differ, depending on the condition of the sperm in the female reproductive tract. Here, we discuss the possibility of biological and clinical studies on human SEMGs conducted using a mouse SVS2 model system; these studies provide new insights into the fertilization process.
@incollection{yoshida_effects_2010,
	address = {New York},
	title = {Effects of the {Seminal} {Plasma} {Proteins} {Semenogelin} ({SEMG})/{Seminal} {Vesicle} {Secretion} 2 ({SVS}2) on {Sperm} {Fertility} pp.205-220},
	isbn = {978-1-60876-401-3},
	url = {https://www.novapublishers.com/catalog/product_info.php?products_id=20256&osCsid=89171514400bb4ac10cbc7ccf5840ea1},
	abstract = {After ejaculation, mammalian spermatozoa need to stay in the female reproductive tract for an appropriate time period before becoming fertilization competent. The molecular, biochemical, and physiological changes that occur to sperm while in the female tract are collectively referred to as capacitation. During this period, seminal plasma can both inhibit and stimulate sperm function and fertility mediated by the multifunctional actions of organic and inorganic components. The major functional proteins isolated and characterized in seminal plasma, which originate in the seminal vesicle, are the semenogelins (SEMGs) SEMG1 and SEMG2 in humans and the homologous protein seminal vesicle secretion 2 (SVS2) in mice. SEMGs are inhibitory factors that affect sperm motility and acrosome reaction. SVS2 also inhibits acrosome reaction and in vitro fertilization (IVF), and this action is considered to be a ―decapacitation factor‖. These proteins can bind to the sperm surface and simultaneously work to precapacitate the spermatozoa, thus shortening their fertilization lifespan. This binding is reversible, but this may differ, depending on the condition of the sperm in the female reproductive tract. Here, we discuss the possibility of biological and clinical studies on human SEMGs conducted using a mouse SVS2 model system; these studies provide new insights into the fertilization process.},
	booktitle = {Human spermatozoa : maturation, capacitation and abnormalities},
	publisher = {Nova Biomedical Books, 2010.},
	author = {Yoshida, K and Iwamoto, T and Yoshida, M},
	editor = {Lejeune, Thomas, Pascal Delvaux},
	year = {2010},
	keywords = {misaki},
	pages = {205--220}
}

Downloads: 0